Nanexa AB Market Cap ($205.22 Million)
Market Cap & Net Worth: Nanexa AB (NANEXA)
Nanexa AB market cap. Nanexa AB (ST:NANEXA) has a market capitalization of $205.22 Million (Skr1.91 Billion) as of November 3, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #16265 globally and #268 in its home market, demonstrating a -3.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanexa AB's stock price Skr10.32 by its total outstanding shares 184786535 (184.79 Million). Also see Nanexa AB cash flow conversion for how efficiently the company converts equity into cash flow.
Nanexa AB Market Cap History (2015–2026)
Nanexa AB market cap history from 2015 to 2026. Data shows growth from $181.22 Million to $205.22 Million (1.30% CAGR). Check current stock price of Nanexa AB for real-time trading data and today's change.
Index Memberships
Nanexa AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.35 Billion | 1.34% | #18 of 281 |
Weight: Nanexa AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nanexa AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanexa AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Nanexa AB to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.45x
Nanexa AB's market cap is 2.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $154.66 Million | $280.00K | -$6.35 Million | 552.35x | N/A |
| 2017 | $113.35 Million | $105.00K | -$7.97 Million | 1079.52x | N/A |
| 2018 | $161.08 Million | $318.84K | -$11.17 Million | 505.20x | N/A |
| 2019 | $207.81 Million | $1.71 Million | -$12.95 Million | 121.53x | N/A |
| 2020 | $235.65 Million | $2.37 Million | -$21.74 Million | 99.56x | N/A |
| 2021 | $79.54 Million | $2.37 Million | -$36.00 Million | 33.51x | N/A |
| 2022 | $55.08 Million | $2.86 Million | -$58.57 Million | 19.26x | N/A |
| 2023 | $24.46 Million | $29.33 Million | -$76.40 Million | 0.83x | N/A |
| 2024 | $42.95 Million | $24.36 Million | -$24.91 Million | 1.76x | N/A |
| 2025 | $88.49 Million | $36.15 Million | -$11.39 Million | 2.45x | N/A |
Competitor Companies of NANEXA by Market Capitalization
Companies near Nanexa AB in the global market cap rankings as of November 3, 2026. Also see NANEXA asset base for a full breakdown of the balance sheet.
Key companies related to Nanexa AB by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Nanexa AB (2015–2026)
Market capitalization of Nanexa AB from 2015 to today. Between 2015 and today, Nanexa AB's market cap moved from $181.22 Million to $ 205.22 Million, with a yearly change of 1.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr205.22 Million | +131.91% |
| 2025 | Skr88.49 Million | +106.02% |
| 2024 | Skr42.95 Million | +75.61% |
| 2023 | Skr24.46 Million | -55.60% |
| 2022 | Skr55.08 Million | -30.75% |
| 2021 | Skr79.54 Million | -66.24% |
| 2020 | Skr235.65 Million | +13.40% |
| 2019 | Skr207.81 Million | +29.01% |
| 2018 | Skr161.08 Million | +42.11% |
| 2017 | Skr113.35 Million | -26.71% |
| 2016 | Skr154.66 Million | -14.66% |
| 2015 | Skr181.22 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Nanexa AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $205.22 Million USD |
| MoneyControl | $205.22 Million USD |
| MarketWatch | $205.22 Million USD |
| marketcap.company | $205.22 Million USD |
| Reuters | $205.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanexa AB
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that ha… Read more